Cancer blood test developer Grail launches trading on Nasdaq, valuing it at about $7 billion
Cancer blood test developer Grail launches trading on Nasdaq, valuing it at about $7 billion
Nearly four years after first pitching for $GRAIL Inc (GRAL.US)$, $Illumina (ILMN.US)$ announced Monday that it would spin off the cancer blood test developer.
在首次推出后近4年,$GRAIL Inc(GRAL.US)$近日宣布将自身的癌症血液检测开发者分拆。$GRAIL Inc (GRAL.US)$, $Illumina (ILMN.US)$近日,$GRAIL Inc(GRAL.US)$宣布将该癌症血液检测开发商分拆。
In July 2021, Illumina said it was committed to re-acquiring Grail.
2021年7月,Illumina表示致力于收购Grail。
Starting today, 25 June, Grail will begin trading the "regular way" under its own Nasdaq ticker, GRAL, as an independent public firm.
从6月25日起,Grail将以其自己的Nasdaq股票代码GRAL作为独立的上市公司进行“常规方式”交易。
Earlier this month, Illumina laid out its plans for the Grail spin-off and said its shareholders will retain their current shares of Illumina common stock and, on the distribution date, also receive one share of GRAIL common stock for every six shares of Illumina common stock.
本月早些时候,Illumina公布了其Grail分拆计划,并表示其股东将保留其当前的Illumina普通股份,并在发行日收到每六股Illumina普通股份换取一股GRAIL普通股份。
Illumina will maintain a 14.5% share of the company.
Illumina将持有该公司14.5%的股份。
As previously disclosed, Illumina entered into a 364-day delayed draw credit agreement that provided for a senior unsecured term loan credit facility in an aggregate principal amount of up to $750 million at a borrowing rate of approximately 6.70%.
正如此前披露的,Illumina签订了一项364天的滞后抽取信贷协议,提供一个高达7.5亿美元的优先无担保期限贷款额度,借款利率约为6.70%。
In December, Illumina agreed to divest Grail as the companies battled with the U.S. and European antitrust regulators for almost three years after announcing the acquisition.
去年12月,Illumina同意出售Grail,因为在宣布收购后的三年里,该公司与美国和欧洲的反垄断监管机构展开了斗争。
In March, an adviser to Europe's top court criticized the decision to block Illumina's $7.1 billion bid for Grail, stating that they exceeded their powers.
今年3月,欧洲最高法院的一名顾问批评了阻止Illumina以71亿美元收购Grail的决定,并称他们超越了其权限。
Last year, in July, the European Commission fined Illumina approximately $463 million (432 million euros), and Grail $1,072 (1,000 euros) for implementing their proposed merger before approval by the commission, in breach of EU merger control rules.
去年7月,欧洲委员会对Illumina处以大约4.63亿美元(4.32亿欧元)的罚款,对Grail处以1,072欧元(1,000欧元)的罚款,原因是在未获批准的情况下实施了他们的拟议合并,违反了欧盟的并购控制规则。
"As we turn the page, we are excited to share our plan to accelerate topline growth, achieve operational excellence, deliver for our customers, and maximize value for shareholders in our upcoming strategy update," said Jacob Thaysen, CEO of Illumina.
Illumina的首席执行官雅各布•塔伊森(Jacob Thaysen)表示:“当我们翻开新的一章时,我们很高兴能够分享我们的计划,即在未来的战略更新中加速营收增长、实现运营卓越、为客户提供服务并最大化股东价值。”
"Illumina is prepared to lead the next era of innovation in next-generation sequencing by continuing to focus on strengthening our business and catalyzing the industry with an even greater focus on our customers' priorities."
“Illumina准备通过继续专注于强化我们的业务,并更加关注客户的优先事项,来引领下一代测序创新的下一个时代。”
Grail CEO Bob Ragusa told Reuters that Grail's cancer blood test, Galleri, can detect multiple types of cancer early and targets 80% of cancers currently not screened for, which results in cancer deaths.
Grail首席执行官鲍勃·雷古萨告诉路透社,Grail的癌症血液检测产品Galleri可以早期检测多种类型的癌症,并针对目前未被筛查的80%的癌症,从而达到预防癌症死亡的效果。
Reuters noted the company is conducting two major clinical trials, one in the U.K., to support an FDA approval application in early 2026. If approved in the U.S., the test could be widely used.
路透社指出,该公司正在进行两项重大的临床试验,其中之一是在英国进行的,以支持在2026年初向美国食品和药物管理局提交批准申请。如果在美国获得批准,该检测产品可能会被广泛应用。